“…Probably, due to the pharmacophoric properties and the lipophilic character of the biphenyl moiety compound 30 proved to be more active toward the cancer cells tested than the simpler analogues 29, 31, 32-34 and those described earlier. [28][29][30] Our data show that the new functionalized pyrrolidines affect the expression of genes involved in cell cycle progression thereby arresting cells in the G2/M phase of cell cycle and causing the upregulation of cell cycle inhibitors CDKN1A and CDKN1C, as well as the downregulation of CDC25A cyclin E1, and of MYBL2 which, conversely, promote cells cycle progression. These experiments establish the new a-mannosidase inhibitors as effective cell cycle modulators.…”